Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402847 | 0.96 | MAPT (0.41) | MAPTPOLBNPC1USP2ALOX15 | |
| SCHEMBL10029314 | 0.96 | MAPT (0.44) | MAPTPOLBNPC1USP2ALOX15 | |
| SCHEMBL4758832 | 0.95 | USP2 (0.41) | MAPTPOLBNPC1USP2ALOX15 | |
| SCHEMBL14369609 | 0.95 | SMN1; SMN2 (0.46) | MAPTPOLBNPC1MAPK1SMN1; SMN2 | |
| SCHEMBL401764 | 0.95 | RECQL (0.47) | MAPTPOLBSMN1; SMN2KMT2ALMNA | |
| SCHEMBL12091364 | 0.95 | MAPT (0.43) | MAPTPOLBNPC1SMN1; SMN2MEN1 | |
| SCHEMBL838083 | 0.95 | MAPT (0.49) | MAPTPOLBNPC1TSHRSMN1; SMN2 | |
| SCHEMBL10030725 | 0.95 | USP2 (0.41) | MAPTPOLBNPC1USP2ALOX15 | |
| SCHEMBL1707907 | 0.95 | USP2 (0.50) | MAPTPOLBNPC1USP2ALOX15 | |
| SCHEMBL4747310 | 0.95 | MAPT (0.40) | MAPTPOLBNPC1USP2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150145920-A1 | METHOD OF JETTING INK | XEROX CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-9022546-B1 | Method of jetting ink | XEROX CORPORATION (US) | 2015-05-05 | — | — | US | disclosed |
| US-9005484-B2 | Low polarity nano silver gels | XEROX CORPORATION (US) | 2015-04-14 | — | — | US | disclosed |
| US-8916084-B2 | Ultra-violet curable gellant inks for three-dimensional printing and digital fabrication applications | XEROX CORPORATION (US) | 2014-12-23 | — | — | US | disclosed |
| US-8791202-B2 | Phase change ink compositions | XEROX CORPORATION (US) | 2014-07-29 | — | — | US | disclosed |
| US-8758865-B2 | Ultra-violet curable gellant inks for tactile and regular print applications for signature and document authentication | XEROX CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8361562-B2 | Ink compositions | XEROX CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120236065-A1 | Magnetic Curable Inks | XEROX CORPORATION (US) | 2012-09-20 | — | — | US | disclosed |
| US-8177897-B2 | Phase change inks containing graphene-based carbon allotrope colorants | XEROX CORPORATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8142557-B2 | Radiation curable ink containing gellant and radiation curable wax | XEROX CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-7625956-B2 | Phase change inks containing photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090258155-A1 | CURABLE OVERCOAT COMPOSITIONS | XEROX CORPORATION (US) | 2009-10-15 | — | — | US | disclosed |
| US-7556844-B2 | Radiation curable photochromic inks | XEROX CORPORATION (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090082489-A1 | Phase change ink compositions | XEROX CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20080000384-A1 | RADIATION CURABLE INK CONTAINING GELLANT AND RADIATION CURABLE WAX | XEROX CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070283846-A1 | Organic Phase Change Carriers Containing Nanoparticles, Phase Change Inks Including Same and Methods for Making Same | XEROX CORPORATION (US) | 2007-12-13 | — | — | US | disclosed |
| US-7279587-B2 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070211110-A1 | RADIATION CURABLE PHOTOCHROMIC INKS | XEROX CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070120910-A1 | Phase change inks containing photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | NR2E3, NR4A1, NR4A3 | MAPT 2052/4885POLB 1052/4885NPC1 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.